News coverage about Smith & Nephew (NYSE:SNN) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Smith & Nephew earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.7721792586665 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of research firms recently commented on SNN. Canaccord Genuity began coverage on shares of Smith & Nephew in a report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price target on the stock. JPMorgan Chase & Co. raised shares of Smith & Nephew from a “neutral” rating to an “overweight” rating in a report on Thursday, January 25th. Zacks Investment Research cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Morgan Stanley cut shares of Smith & Nephew from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.00.

Shares of Smith & Nephew (NYSE:SNN) traded down $0.06 during mid-day trading on Tuesday, reaching $36.74. 78,104 shares of the company’s stock were exchanged, compared to its average volume of 485,455. The company has a current ratio of 2.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Smith & Nephew has a 1-year low of $29.76 and a 1-year high of $40.43.

ILLEGAL ACTIVITY WARNING: This piece was reported by Marea Informative and is owned by of Marea Informative. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.mareainformativa.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-smith-nephew-snn-share-price-updated-updated-updated/126983/.

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.